Modeling huntington disease in yeast: Perspectives and future directions

Prion

Volumn 5, Issue 4, 2011, Pages 269-276

  Mason, Robert P ^a   Giorgini, Flaviano ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Genetic modifiers; Huntington disease; Neurodegeneration; Prions; Yeast

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN; POLYGLUTAMINE; PROLINE RICH PROTEIN;

CYTOTOXICITY; DISEASE MODEL; DROSOPHILA; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUNTINGTON CHOREA; MAMMAL CELL; MOLECULAR MECHANICS; NONHUMAN; PRION; PROTEIN FOLDING; REVIEW; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; HUNTINGTON DISEASE; PEPTIDES; PRIONS; PROTEIN FOLDING; RECOMBINANT FUSION PROTEINS; SACCHAROMYCES CEREVISIAE;

EID: 83755178417     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.5.4.18005     Document Type: Review

References (120)

1. Sicard D, Legras JL. Bread, beer and wine: yeast domestication in the Saccharomyces sensu stricto complex. C R Biol 2011; 334:229-36.
2. Pasteur L. Mémoire (memoire) sur le fermentation alcoolique. Annales de Chimie 1860; 58:323-426.
3. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83.
4. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90:549-58. (Pubitemid 27347244)
5. Martin JB, Gusella JF. Huntington's disease. Pathogenesis and management. N Engl J Med 1986; 315:1267-76.
6. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985; 227:770-3. (Pubitemid 15168268)
7. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277:1990-3. (Pubitemid 27449140)
8. McNeil SM, Novelletto A, Srinidhi J, Barnes G, Kornbluth I, Altherr MR, et al. Reduced penetrance of the Huntington's disease mutation. Hum Mol Genet 1997; 6:775-9. (Pubitemid 27199071)
9. Quarrell OW, Rigby AS, Barron L, Crow Y, Dalton A, Dennis N, et al. Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. J Med Genet 2007; 44:68.
10. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004; 65:267-77. (Pubitemid 38443548)
11. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004; 101:3498-503.
12. Metzger S, Rong J, Nguyen HP, Cape A, Tomiuk J, Soehn AS, et al. Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease. Hum Mol Genet 2008; 17:1137-46. (Pubitemid 351494185)
13. Weydt P, Soyal SM, Gellera C, Didonato S, Weidinger C, Oberkofler H, et al. The gene coding for PGC-1alpha modifies age at onset in Huntington's Disease. Mol Neurodegener 2009; 4:3.
14. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431:805-10. (Pubitemid 39434070)
15. Hatters DM. Protein misfolding inside cells: the case of huntingtin and Huntington's disease. IUBMB Life 2008; 60:724-8.
16. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 2004; 5:958-63. (Pubitemid 39534452)
17. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10:83-98.
18. Rubinsztein DC. Lessons from animal models of Huntington's disease. Trends Genet 2002; 18:202-9. (Pubitemid 34273741)
19. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 2003; 100:5950-5. (Pubitemid 36576913)
20. Bates GP, Gonitel R. Mouse models of triplet repeat diseases. Mol Biotechnol 2006; 32:147-58. (Pubitemid 43170243)
21. Ferrante RJ. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 2009; 1792:506-20.
22. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 2000; 9:2799-809.
23. Xi Y, Noble S, Ekker M. Modeling neurodegeneration in zebrafish. Curr Neurol Neurosci Rep 11:274-82.
24. Marsh JL, Pallos J, Thompson LM. Fly models of Huntington's disease. Hum Mol Genet 2003; 12:187-93.
25. Ambegaokar SS, Roy B, Jackson GR. Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease and amyotrophic lateral sclerosis. Neurobiol Dis 2010; 40:29-39.
26. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci USA 2001; 98:13318-23. (Pubitemid 33051360)
27. Hartwell LH, Culotti J, Reid B. Genetic control of the cell-division cycle in yeast. I. Detection of mutants. Proc Natl Acad Sci USA 1970; 66:352-9.
28. Goffeau A, Barrell BG, Bussey H, Davis RW, Dujon B, Feldmann H, et al. Life with 6,000 genes. Science 1996; 274:546-63.
29. Christie KR, Hong EL, Cherry JM. Functional annotations for the Saccharomyces cerevisiae genome: the knowns and the known unknowns. Trends Microbiol 2009; 17:286-94.
30. Karathia H, Vilaprinyo E, Sorribas A, Alves R. Saccharomyces cerevisiae as a model organism: a comparative study. PLoS One 2011; 6:16015.
31. Petranovic D, Tyo K, Vemuri GN, Nielsen J. Prospects of yeast systems biology for human health: integrating lipid, protein and energy metabolism. FEMS Yeast Res 2010; 10:1046-59.
32. Zhang N, Osborn M, Gitsham P, Yen K, Miller JR, Oliver SG. Using yeast to place human genes in functional categories. Gene 2003; 303:121-9. (Pubitemid 36151776)
33. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999; 285:901-6. (Pubitemid 29381993)
34. Gelperin DM, White MA, Wilkinson ML, Kon Y, Kung LA, Wise KJ, et al. Biochemical and genetic analysis of the yeast proteome with a movable ORF collection. Genes Dev 2005; 19:2816-26. (Pubitemid 41739967)
35. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, et al. The genetic landscape of a cell. Science 2010; 327:425-31.
36. Aldred PM, Borts RH. Humanizing mismatch repair in yeast: towards effective identification of hereditary non-polyposis colorectal cancer alleles. Biochem Soc Trans 2007; 35:1525-8.
37. Nolden M, Ehses S, Koppen M, Bernacchia A, Rugarli EI, Langer T. The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria. Cell 2005; 123:277-89. (Pubitemid 41457217)
38. Foury F, Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett 1997; 411:373-7. (Pubitemid 27301488)
39. Fushimi K, Long C, Jayaram N, Chen X, Li L, Wu JY. Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell 2011; 2:141-9.
40. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci USA 2008; 105:6439-44. (Pubitemid 351758364)
41. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, et al. A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 2011; 9:1001052.
42. Kryndushkin D, Wickner RB, Shewmaker F. FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein Cell 2011; 2:223-36.
43. Kunst CB, Mezey E, Brownstein MJ, Patterson D. Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat Genet 1997; 15:91-4. (Pubitemid 27014957)
44. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, Sherman MY. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 2002; 157:997-1004. (Pubitemid 34839774)
45. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003; 302:1772-5. (Pubitemid 37505742)
46. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 2011; 9:1000614.
47. Braun RJ, Buttner S, Ring J, Kroemer G, Madeo F. Nervous yeast: modeling neurotoxic cell death. Trends Biochem Sci 2010; 35:135-44.
48. Winderickx J, Delay C, De Vos A, Klinger H, Pellens K, Vanhelmont T, et al. Protein folding diseases and neurodegeneration: lessons learned from yeast. Biochim Biophys Acta 2008; 1783:1381-95.
49. Duennwald ML. Monitoring polyglutamine toxicity in yeast. Methods 2011; 53:232-7.
50. Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, et al. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull 2007; 72:83-97. (Pubitemid 46367466)
51. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 2006; 15:273-85. (Pubitemid 43125981)
52. Hughes RE, Lo RS, Davis C, Strand AD, Neal CL, Olson JM, et al. Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci USA 2001; 98:13201-6. (Pubitemid 33051340)
53. Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci USA 2000; 97:1589-94. (Pubitemid 30118486)
54. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci USA 2000; 97:7841-6. (Pubitemid 30460735)
55. Gokhale KC, Newnam GP, Sherman MY, Chernoff YO. Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model. J Biol Chem 2005; 280:22809-18. (Pubitemid 40853187)
56. Dehay B, Bertolotti A. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem 2006; 281:35608-15. (Pubitemid 46041291)
57. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci USA 2006; 103:11045-50. (Pubitemid 44148415)
58. Duennwald ML, Jagadish S, Giorgini F, Muchowski PJ, Lindquist S. A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci USA 2006; 103:11051-6. (Pubitemid 44148416)
59. Wang Y, Meriin AB, Zaarur N, Romanova NV, Chernoff YO, Costello CE, et al. Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J 2009; 23:451-63.
60. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004; 304:100-4. (Pubitemid 38451465)
61. Douglas PM, Summers DW, Ren HY, Cyr DM. Reciprocal efficiency of RNQ1 and polyglutamine detoxification in the cytosol and nucleus. Mol Biol Cell 2009; 20:4162-73.
62. Sokolov S, Pozniakovsky A, Bocharova N, Knorre D, Severin F. Expression of an expanded polyglutamine domain in yeast causes death with apoptotic markers. Biochim Biophys Acta 2006; 1757:660-6.
63. Meriin AB, Zhang X, Miliaras NB, Kazantsev A, Chernoff YO, McCaffery JM, et al. Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis. Mol Cell Biol 2003; 23:7554-65. (Pubitemid 37271456)
64. Muchowski PJ, Ning K, D'Souza-Schorey C, Fields S. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci USA 2002; 99:727-32. (Pubitemid 34106578)
65. Ocampo A, Zambrano A, Barrientos A. Suppression of polyglutamine-induced cytotoxicity in Saccharomyces cerevisiae by enhancement of mitochondrial biogenesis. FASEB J 2010; 24:1431-41.
66. Solans A, Zambrano A, Rodriguez M, Barrientos A. Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet 2006; 15:3063-81. (Pubitemid 44530710)
67. Engqvist-Goldstein AE, Drubin DG. Actin assembly and endocytosis: from yeast to mammals. Annu Rev Cell Dev Biol 2003; 19:287-332. (Pubitemid 37487351)
68. Qin ZH, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, et al. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 2004; 24:269-81. (Pubitemid 38181691)
69. Truant R, Atwal R, Burtnik A. Hypothesis: Huntingtin may function in membrane association and vesicular trafficking. Biochem Cell Biol 2006; 84:912-7.
70. Trushina E, Dyer RB, Badger JD, 2nd, Ure D, Eide L, Tran DD, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 2004; 24:8195-209. (Pubitemid 39167467)
71. Gray SG. Targeting histone deacetylases for the treatment of Huntington's disease. CNS Neurosci Ther 2010; 16:348-61.
72. Giorgini F, Moller T, Kwan W, Zwilling D, Wacker JL, Hong S, et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia and mice expressing a mutant huntingtin fragment. J Biol Chem 2008; 283:7390-400.
73. Tauber E, Miller-Fleming L, Mason RP, Kwan W, Clapp J, Butler NJ, et al. Functional gene expression profiling in yeast implicates translational dysfunction in mutant huntingtin toxicity. J Biol Chem 2011; 286:410-9.
74. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292:1552-5. (Pubitemid 32493425)
75. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, et al. Global changes to the ubiquitin system in Huntington's disease. Nature 2007; 448:704-8. (Pubitemid 47236860)
76. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 2004; 23:4307-18. (Pubitemid 39546168)
77. Duennwald ML, Lindquist S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev 2008; 22:3308-19.
78. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005; 37:526-31. (Pubitemid 40617282)
79. Bossy-Wetzel E, Petrilli A, Knott AB. Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci 2008; 31:609-16.
80. Oliveira JM. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J Neurochem 2010; 114:1-12.
81. Bocharova NA, Sokolov SS, Knorre DA, Skulachev VP, Severin FF. Unexpected link between anaphase promoting complex and the toxicity of expanded polyglutamines expressed in yeast. Cell Cycle 2008; 7:3943-6.
82. Wickner RB, Edskes HK, Shewmaker F, Nakayashiki T, Engel A, McCann L, et al. Yeast prions: evolution of the prion concept. Prion 2007; 1:94-100.
83. +] seeds necessary for prion propagation. EMBO J 2007; 26:3794-803.
84. Douglas PM, Treusch S, Ren HY, Halfmann R, Duennwald ML, Lindquist S, et al. Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci USA 2008; 105:7206-11. (Pubitemid 351754456)
85. Tipton KA, Verges KJ, Weissman JS. In vivo monitoring of the prion replication cycle reveals a critical role for Sis1 in delivering substrates to Hsp104. Mol Cell 2008; 32:584-91.
86. Derkatch IL, Uptain SM, Outeiro TF, Krishnan R, Lindquist SL, Liebman SW. Effects of Q/N-rich, polyQ and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro. Proc Natl Acad Sci USA 2004; 101:12934-9. (Pubitemid 39167561)
87. Derkatch IL, Bradley ME, Hong JY, Liebman SW. Prions affect the appearance of other prions: the story of [PIN(+)]. Cell 2001; 106:171-82. (Pubitemid 32772628)
88. Urakov VN, Vishnevskaya AB, Alexandrov IM, Kushnirov VV, Smirnov VN, Ter-Avanesyan MD. Interdependence of amyloid formation in yeast: implications for polyglutamine disorders and biological functions. Prion 4:45-52.
89. Wang Y, Meriin AB, Costello CE, Sherman MY. Characterization of proteins associated with polyglutamine aggregates: a novel approach towards isolation of aggregates from protein conformation disorders. Prion 2007; 1:128-35.
90. Furukawa Y, Kaneko K, Matsumoto G, Kurosawa M, Nukina N. Cross-seeding fibrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine diseases. J Neurosci 2009; 29:5153-62.
91. Nucifora FC Jr, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291:2423-8. (Pubitemid 32231807)
92. Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 2004; 15:95-105. (Pubitemid 38850222)
93. Manogaran AL, Fajardo VM, Reid RJ, Rothstein R, Liebman SW. Most, but not all, yeast strains in the deletion library contain the [PIN(+)] prion. Yeast 2010; 27:159-66.
94. Manogaran AL, Hong JY, Hufana J, Tyedmers J, Lindquist S, Liebman SW. Prion formation and polyglutamine aggregation are controlled by two classes of genes. PLoS Genet 2011; 7:1001386.
95. Zhou P, Derkatch IL, Liebman SW. The relationship between visible intracellular aggregates that appear after overexpression of Sup35 and the yeast prion-like elements [PSI(+)] and [PIN(+)]. Mol Microbiol 2001; 39:37-46. (Pubitemid 32057674)
96. Bailleul-Winslett PA, Newnam GP, Wegrzyn RD, Chernoff YO. An antiprion effect of the anticytoskeletal drug latrunculin A in yeast. Gene Expr 2000; 9:145-56. (Pubitemid 32180168)
97. Ganusova EE, Ozolins LN, Bhagat S, Newnam GP, Wegrzyn RD, Sherman MY, et al. Modulation of prion formation, aggregation and toxicity by the actin cytoskeleton in yeast. Mol Cell Biol 2006; 26:617-29. (Pubitemid 43089773)
98. Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 2003; 302:1769-72. (Pubitemid 37505741)
99. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Targeting kynurenine-3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets 2010; 9:791-800.
100. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, et al. The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease. Curr Biol 2011; 21:961-6.
101. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011; 145:863-74.
102. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA 2006; 103:4246-51.
103. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechin- gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 2006; 15:2743-51. (Pubitemid 44400401)
104. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci USA 2005; 102:892-7. (Pubitemid 40282761)
105. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, et al. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci USA 2007; 104:16685-9. (Pubitemid 350211077)
106. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006; 313:324-8. (Pubitemid 44480951)
107. Liang J, Clark-Dixon C, Wang S, Flower TR, Williams-Hart T, Zweig R, et al. Novel suppressors of alpha-synuclein toxicity identified using yeast. Hum Mol Genet 2008; 17:3784-95.
108. Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, et al. Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet 2009; 41:316-23.
109. Zabrocki P, Bastiaens I, Delay C, Bammens T, Ghillebert R, Pellens K, et al. Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. Biochim Biophys Acta 2008; 1783:1767-80.
110. Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, et al. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet 2010; 6:1000902.
111. Bharadwaj P, Martins R, Macreadie I. Yeast as a model for studying Alzheimer's disease. FEMS Yeast Res 2010; 10:961-9.
112. Gunther MR, Vangilder R, Fang J, Beattie DS. Expression of a familial amyotrophic lateral sclerosis-associated mutant human superoxide dismutase in yeast leads to decreased mitochondrial electron transport. Arch Biochem Biophys 2004; 431:207-14. (Pubitemid 39369926)
113. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem 2009; 284:20329-39.
114. Nishida CR, Gralla EB, Valentine JS. Characterization of three yeast copper-zinc superoxide dismutase mutants analogous to those coded for in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1994; 91:9906-10. (Pubitemid 24311917)
115. Chernoff YO. Stress and prions: lessons from the yeast model. FEBS Lett 2007; 581:3695-701. (Pubitemid 47081006)
116. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science 2007; 318:930-6. (Pubitemid 350098981)
117. Knight SA, Kim R, Pain D, Dancis A. The yeast connection to Friedreich ataxia. Am J Hum Genet 1999; 64:365-71.
118. Berger AC, Hanson PK, Wylie Nichols J, Corbett AH. A yeast model system for functional analysis of the Niemann-Pick type C protein 1 homolog, Ncr1p. Traffic 2005; 6:907-17. (Pubitemid 41309399)
119. Phillips SN, Muzaffar N, Codlin S, Korey CA, Taschner PE, de Voer G, et al. Characterizing pathogenic processes in Batten disease: use of small eukaryotic model systems. Biochim Biophys Acta 2006; 1762:906-19.
120. Pearce DA. Hereditary spastic paraplegia: mitochondrial metalloproteases of yeast. Hum Genet 1999; 104:443-8. (Pubitemid 29370917)